Kit Check announces issuance of four meaningful patents by U.S. Patent and Trademark Office

Kit Check™ (http://kitcheck.com), the leader in hospital pharmacy kit processing and medication tracking software, today announced that the United States Patent and Trademark Office has issued the company two meaningful patents, with two additional patents set to issue on June 16, 2015. These awards represent a robust portfolio of intellectual property (IP) related to the Kit Check product.

The two patents granted to Kit Check are U.S. Patent Numbers 8,990,099 and 9,037,479. The two additional patents are expected to issue as U.S. Patent Numbers 9,058,412 and 9,058,413.

"Kit Check was founded on innovations for medication tracking and processing. Our engineering team invented hospital pharmacy kit restocking automation and has applied these unique technologies and approaches to other areas of hospital medication tracking. We are pleased the U.S. Patent and Trademark Office agreed our inventions are meaningful and merit patent protection," said Kit Check co-founder and chief product officer Tim Kress-Spatz.

Kit Check's management team believes these patents represent significant intellectual property protection while providing assurance to Kit Check customers that the innovative technology is unique and protected. The Kit Check team expects this growing patent portfolio to be further augmented as the company continues to innovate.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CHOP study shows safety of rotavirus vaccine in neonatal intensive care unit